InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,626.02
(
0.54%
)
US TECH 100
18,958.84
(
-0.29%
)
Dow Jones
41,393.78
(
0.00%
)
Brent Oil
71.80
(
0.57%
)
Bitcoin
58,738.70
(
-0.74%
)
Post# of 253125
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 839
Posts 120436
Boards Moderated 18
Alias Born 09/05/2002

DewDiligence

Member Level

Re: jq1234 post# 119060

Thursday, 04/28/2011 9:30:55 PM

Thursday, April 28, 2011 9:30:55 PM

Post# of 253125
It’s excellent news for MNTA investors that an FDA staffer cites MNTA’s generic Lovenox as the impetus for the FDA’s going “one step further” than the EMA is enabling biogenerics. This is consistent with Craig Wheeler’s claim that the FDA’s requirements for generic Lovenox were essentially crafted by MNTA itself.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up